Humacyte director awarded options for 80,000 shares

Humacyte, Inc. director Brady W. Dougan received a grant of stock options to acquire common shares.

Rhea-AI Filing Summary

Humacyte, Inc. director Brady W. Dougan received a grant of stock options to acquire common shares. The award covers options exercisable for 80,000 shares of Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036.

The options were granted as compensation and do not reflect an open-market purchase or sale. According to the vesting terms, 25% of the options become exercisable on June 11, 2027, with the remaining options vesting in equal monthly installments through June 11, 2030.

Insider Trade Summary

Grant/Award: 0 shares

Grant/Award 1 txn

Insider Dougan Brady W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	0	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 0 contracts (Direct)

Footnotes (1)

1. F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

Key Figures

Options underlying shares: 80,000 shares Exercise price: $1.08 per share Expiration date: June 11, 2036 +3 more

6 metrics

Options underlying shares 80,000 shares Stock options grant to director

Exercise price $1.08 per share Strike price for options

Expiration date June 11, 2036 Option term end

Initial vesting date June 11, 2027 First 25% of options vest

Final vesting date June 11, 2030 Monthly vesting completes

Vesting schedule 1/48 monthly after first 25% Remaining options vesting pattern

Key Terms

Stock Options (right to buy), exercise price, expiration date, vest

4 terms

Stock Options (right to buy) financial

"security_title: Stock Options (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest financial

"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Humacyte (HUMA) director receive in this Form 4 filing?

The director received a grant of stock options covering 80,000 Humacyte common shares. These options are a compensation award, not an open-market trade, and give the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the new Humacyte (HUMA) stock options?

The options have an exercise price of $1.08 per share. This means the director can later buy Humacyte common stock at $1.08, regardless of future market price, once the options have vested and before they expire.

When do the Humacyte (HUMA) stock options granted to the director vest?

The first 25% of the options vest on June 11, 2027. The remaining 75% then vest in equal monthly installments, with 1/48 of the award vesting each month until all options are fully vested by June 11, 2030.

When do the newly granted Humacyte (HUMA) stock options expire?

The options expire on June 11, 2036. If the director does not exercise them by that date, they will lapse, and the right to buy Humacyte common shares at $1.08 per share will be lost.

Did the Humacyte (HUMA) director buy or sell shares in this Form 4?

No, this filing reports a grant of stock options, not a share purchase or sale. The director acquired rights to buy 80,000 shares later; no common shares were bought or sold in the market in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dougan Brady W

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.08	06/11/2026		A		0		(1)	06/11/2036	Common Stock	80,000	$0	0	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

	/s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)